Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OneMedNet (ONMD) Gains from Sales and Divestitures (2022 - 2025)

OneMedNet has reported Gains from Sales and Divestitures over the past 4 years, most recently at $1.2 million for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 519.54% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 519.54% year-over-year, with the annual reading at $1.2 million for FY2025, 519.54% up from the prior year.
  • Gains from Sales and Divestitures was $1.2 million for Q4 2025 at OneMedNet, up from $200000.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $177.3 million in Q4 2022 and troughed at $200000.0 in Q4 2024.
  • The 4-year median for Gains from Sales and Divestitures is $752496.0 (2023), against an average of $44.7 million.
  • Year-over-year, Gains from Sales and Divestitures tumbled 99.85% in 2023 and then surged 519.54% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $177.3 million in 2022, then tumbled by 99.85% to $265914.0 in 2023, then dropped by 24.79% to $200000.0 in 2024, then surged by 519.54% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ONMD's Gains from Sales and Divestitures are $1.2 million (Q4 2025), $200000.0 (Q4 2024), and $265914.0 (Q4 2023).